Stocksigma LogoStocksigma Logo

Bharat Parenterals Q2 FY27 Consolidated Results And Growth Strategy

Bharat Parenterals reported consolidated Q2 FY27 revenue of ₹136.3 Cr (+110.9% YoY, +45.4% QoQ), with operating EBITDA surging to ₹23.6 Cr (17.3% margin)

Bharat Parenterals Q2 FY27 Consolidated Results And Growth Strategy

Bharat Parenterals Ltd · Investor Presentation · 29 Oct 2026, 10:44 pm

Bharat Parenterals Q2 FY27 Consolidated Results And Growth Strategy Bharat Parenterals reported consolidated Q2 FY27 revenue of ₹136.3 Cr (+110.9% YoY, +45.4% QoQ), with operating EBITDA surging to ₹23.6 Cr (17.3% margin) and PAT reaching ₹11.8 Cr (₹9.4 Cr to owners), driven by subsidiary Innoxel's turnaround to ₹5.4 Cr PAT and ₹44.5 Cr revenue (+253.1% YoY). BPL Standalone generated ₹78.6 Cr revenue (+88.4% YoY) with ₹117.83 Cr in orders as of 30th Sep'26. Additionally, the company approved a ₹139 Cr preferential issue to fund expansion, including Varenyam Bio’s revised ₹300 Cr biologics CDMO facility.

Original exchange filing (PDF)

More announcements from Bharat Parenterals Ltd

All Bharat Parenterals Ltd announcements